Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03854110 · ClinicalTrials.gov registry record · Phase 1
Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine
A Phase 1 study of Pancreatic Cancer, Adult, sponsored by Geistlich Pharma.
- Active
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
- 5
- Study locations
NCT03854110 is a Phase 1 study of Pancreatic Cancer, Adult that is active but no longer recruiting, run by Geistlich Pharma. The registered enrollment target is 64 participants, below the 489-participant average among 3 other Pancreatic Cancer, Adult trials with a reported enrollment target (87% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT03854110, a Phase 1 study of Pancreatic Cancer, Adult, is active but no longer recruiting, sponsored by Geistlich Pharma.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a phase 1 first in human, dose escalation trial of GP-2250 administered in combination with gemcitabine in subjects with advanced pancreatic cancer previously treated with 5-fluorouracil-based chemotherapy. Prior radiosensitization with gemcitabine, the use of 5-fluorouracil, FOLFIRINOX or Nab-paclitaxel/gemcitabine in the neoadjuvant setting, and prior pancreaticoduodenectomy (Whipple procedure) is allowed. If prior treatment with gemcitabine was at therapeutic doses, a minimum of 3 months must have elapsed since the end of such treatment. As a precursor to 5-FU use of capecitabine-based chemotherapy is also permitted.
Conditions Studied
Interventions
- DRUG GP-2250
Study Locations (5)
California
- Hoag Family Cancer Institute - Newport Beach
Kansas
- University of Kansas Cancer Center - Fairway
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
North Carolina
- Wake Forest Baptist Health - Winston-Salem
Pennsylvania
- Abramson Cancer Center at the University of Pennsylvania - Phildelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2019-01-14 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03854110
The ClinicalTrials.gov registry entry for NCT03854110 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 489-participant average among 3 other Pancreatic Cancer, Adult trials with a reported enrollment target (87% lower). The listed sponsor is Geistlich Pharma, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Cancer, Adult appearing as the primary indexed condition, and to 1 intervention - of which GP-2250 is the first listed.
NCT03854110 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Kansas, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03854110 about?
NCT03854110 is a clinical study titled "Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine". This is a phase 1 first in human, dose escalation trial of GP-2250 administered in combination with gemcitabine in subjects with advanced pancreatic cancer previously treated with 5-fluorouracil-based chemotherapy. Prior radiosensitization with gemcitabine, the use of 5-fluorouracil, FOLFIRINOX or ...
What is the current status of trial NCT03854110?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2019-01-14. Estimated completion is 2026-06-30.
What conditions does trial NCT03854110 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Adult.
What interventions are being tested in trial NCT03854110?
The interventions under investigation include: GP-2250 (DRUG).
Who is sponsoring clinical trial NCT03854110?
This trial is sponsored by Geistlich Pharma, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03854110 being conducted?
This trial has 5 study locations across California, Kansas, Massachusetts, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer, Adult
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.